NextPlat Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NextPlat Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $5.87M | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $5.73M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.00M | Mar 29, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $11.71M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $7.74M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.69M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $5.87M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.73M | Mar 30, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $6.00M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $4.70M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.95M | Apr 7, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.91M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $17.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.31M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $2.49M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.86M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.23M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $1.22M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.03M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.15M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.08M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($14.03M) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | ($3.78M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($9.16M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($8.11M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.76M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($1.38M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($1.19M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.94M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($2.59M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($2.06M) | Apr 7, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.00M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($23.03M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($23.23M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($7.20M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($6.62M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.03M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($1.11M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($1.13M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.58M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.63M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 4, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Apr 4, 2022 |
| FY2018 | Dec 31, 2018 | $0 | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $50.0K | Apr 7, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 30, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.18M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.91M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $5.09M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $5.13M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $694.4K | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $761.2K | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $664.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $583.9K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $566.2K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.13M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($5.46M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.60M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($3.60M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($4.09M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($837.0K) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($659.2K) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($590.2K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($315.2K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($1.04M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $189.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $647.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $716.0K | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $229.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $34.9K | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $70.2K | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $30.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $33.2K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $26.4K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.47M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $37.08M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $64.47M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $28.64M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $20.57M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.63M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $2.43M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $2.44M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.60M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $3.03M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.38M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $2.87M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $3.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.07M | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $1.79M | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.06M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.20M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $720.6K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.31M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $27.28M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $32.18M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $25.78M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $17.53M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $565.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $639.7K | Apr 4, 2022 |
| FY2020 | Dec 31, 2018 | $1.38M | Mar 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.86M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $2.31M | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $156.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $731.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 11, 2024 |
| FY2023 | Dec 31, 2021 | $0 | Apr 11, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.06M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($48.35M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($34.93M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($31.15M) | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | ($21.99M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($13.88M) | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | ($11.12M) | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | ($9.74M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($8.54M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($4.60M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.71M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $19.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $26.31M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $18.89M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | $17.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $728.8K | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | $75.4K | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | $142.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $233.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $114.7K | Apr 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $1.41M | Mar 24, 2025 |
| FY2023 | Dec 31, 2023 | $1.52M | Apr 11, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2017 | Dec 31, 2017 | (8) | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | (11) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 7, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 26, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 11, 2024 |
| FY2017 | Dec 31, 2017 | (8) | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | (11) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 7, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 26, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 26.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 25.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 18.72M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 14.40M | Apr 11, 2024 |
| FY2022 | Dec 31, 2021 | 7.05M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 817,450 | Apr 4, 2022 |
| FY2020 | Dec 31, 2019 | 121,216 | Mar 22, 2021 |
| FY2019 | Dec 31, 2018 | 62,435 | Mar 30, 2020 |
| FY2018 | Mar 8, 2018 | 140.22M | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | 936,519 | Mar 29, 2019 |